



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
Frontiers Production Office,  
production.office@frontiersin.org

SPECIALTY SECTION  
This article was submitted to Molecular  
Diagnostics and Therapeutics,  
a section of the journal  
Frontiers in Molecular Biosciences

RECEIVED 10 November 2022  
ACCEPTED 10 November 2022  
PUBLISHED 01 December 2022

CITATION  
Frontiers Production Office (2022),  
Erratum: Construction of a tumor  
immune infiltration macrophage  
signature for predicting prognosis and  
immunotherapy response in  
liver cancer.  
*Front. Mol. Biosci.* 9:1094902.  
doi: 10.3389/fmolb.2022.1094902

COPYRIGHT  
© 2022 Frontiers Production Office.  
This is an open-access article  
distributed under the terms of the  
[Creative Commons Attribution License  
\(CC BY\)](#). The use, distribution or  
reproduction in other forums is  
permitted, provided the original  
author(s) and the copyright owner(s) are  
credited and that the original  
publication in this journal is cited, in  
accordance with accepted academic  
practice. No use, distribution or  
reproduction is permitted which does  
not comply with these terms.

# Erratum: Construction of a tumor immune infiltration macrophage signature for predicting prognosis and immunotherapy response in liver cancer

Frontiers Production Office\*

Frontiers Media SA, Lausanne, Switzerland

## KEYWORDS

macrophage, tumor microenvironment, immune infiltration, prognosis, immunotherapy response

## An Erratum on

### Construction of a tumor immune infiltration macrophage signature for predicting prognosis and immunotherapy response in liver cancer


by Huang A, Lv B, Zhang Y, Yang J, Li J, Li C, Yu Z and Xia J (2022). *Front. Mol. Biosci.* 9:983840. doi: 10.3389/fmolb.2022.983840


Due to a production error, there was a mistake in **Figures 6–10** as published. The image intended for **Figure 10** was captioned as **Figure 6**, which resulted in **Figures 6–9** to be transposed to captions 7–10. The corrected figures and captions appear below.

The publisher apologizes for this mistake. The original version of this article has been updated.

## Publisher's note


All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.






**FIGURE 7**


Immunotherapy response with TIMSig. (A,B) Comparison of the expression value of immune checkpoints (PD1, PDL1, and CTLA4) with different groups of TIMSig in each cohort. (C–E) The Pearson correlation between immune checkpoints and the risk scores in the TCGA cohort. (F–H) K–M survival curves of OS among four patient groups stratified by the TIMSig and PD1, PDL1, and CTLA4 in the TCGA cohort. (I) Comparison of the risk score with different groups of PD1/PDL1 therapy responses, paired t-test was used as the significance test. (J) The ROC curve to estimate the sensitivity of TIMSig to PD1/PDL1 therapy responses. (K) K–M survival curves of PFS among four patient groups stratified by the TIMSig and PD1/PDL1 therapy responses.



**FIGURE 8**

Tumor immune microenvironment analyses. **(A)** Correlation between the immune score and risk score in TCGA cancer samples. **(B)** Correlation between the ESTIMATE score and risk score in TCGA cancer samples. **(C)** Correlation between the tumor purity and risk score in TCGA cancer samples. **(D–G)** Identification of TIMGs associated with TIICs.





**FIGURE 10**

Chemotherapeutic drug sensitivity analysis based on TIMSig. (A–F) Comparison of the IC50 levels (cytarabine, rapamycin, cisplatin, sunitinib, erlotinib, and methotrexate) with different groups of TIMSig in the TCGA cohort.